Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-2248.76%
operating margin TTM
-2778.89%
revenue TTM
8.78 Million
revenue per share TTM
0.13$
valuation ratios | |
|---|---|
| pe ratio | -6.47 |
| peg ratio | -1.66 |
| price to book ratio | 1.37 |
| price to sales ratio | 150.07 |
| enterprise value multiple | -5.62 |
| price fair value | 1.37 |
profitability ratios | |
|---|---|
| gross profit margin | 77.61% |
| operating profit margin | -2778.89% |
| pretax profit margin | -2248.76% |
| net profit margin | -2248.76% |
| return on assets | -19.92% |
| return on equity | -19.82% |
| return on capital employed | -25.91% |
liquidity ratio | |
|---|---|
| current ratio | 18.91 |
| quick ratio | 18.91 |
| cash ratio | 0.72 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 36.40 |
| days of payables outstanding | 758.09 |
| cash conversion cycle | -721.70 |
| receivables turnover | 10.03 |
| payables turnover | 0.48 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -41.38 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.46 |
| cash per share | 11.26 |
| operating cash flow per share | -2.45 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -41.38 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -208.70 |
Frequently Asked Questions
When was the last time Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported earnings?
Celldex Therapeutics, Inc. (CLDX) published its most recent earnings results on 06-11-2024.
What is Celldex Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Celldex Therapeutics, Inc. (NASDAQ:CLDX)'s trailing twelve months ROE is -19.82%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Celldex Therapeutics, Inc. (CLDX) currently has a ROA of -19.92%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CLDX's net profit margin stand at?
CLDX reported a profit margin of -2248.76% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CLDX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 18.91 in the most recent quarter. The quick ratio stood at 18.91, with a Debt/Eq ratio of 0.01.